Non-invasive insights that
transform cancer care
DNA methylation patterns act as highly sensitive biomarkers for cancer detection and monitoring. At YD Bio, we are harnessing this powerful epigenetic signal to develop blood-based tests that provide clinicians with early, accurate insights into disease. Our platform is designed to help guide treatment, track response, and monitor recurrence—improving decision-making and outcomes for patients.
Why DNA Methylation Matters
Early detection:
DNA methylation changes appear at the earliest stages of tumor development, enabling diagnosis before clinical symptoms.
Broader coverage:
Unlike traditional biomarkers , which detect only a portion of cases, methylation analysis captures a wider spectrum of cancers.
Real-time monitoring:
Allows clinicians to assess treatment effectiveness and detect recurrence sooner, with a simple blood draw.
Key Features of Our DNA Methylation Platform
Demonstrated High Accuracy
Sensitivity: Achieved promising results in early-stage cancer detection and monitoring during clinical studies.
Specificity: Designed to reduce false positives and support more reliable decision-making.
Cost-Effective
and Scalable
qPCR-based platform under development aims to deliver an affordable solution without compromising analytical accuracy.
Scalable infrastructure designed to support broad adoption across clinical research and future detection applications.
Streamlined
Workflow
Simplified, user-friendly sample collection and analysis workflows minimize complexity for clinicians and laboratories.
Results are integrated through the EG Biocloud Report System, enabling seamless incorporation into clinical research and workflows.
Room Temperature
Stability
Samples remain stable for up to 5 days at room temperature under controlled conditions.
Simplifies logistics, reduces operational costs, and expands accessibility for broader patient populations.